Dr K C Yadav

Efficacy of vilanterol-fluticasone furoate versus formoterol-budesonide combination therapy in stable asthma

181 Views Original Article

The present study evaluates the efficacy of Vilanterol-Fluticasone Furoate (VI-FF) versus Formoterol-Budesonide (FM-BD) combination therapy in stable asthma. Both regimens led to significant improvements in asthma control, as evidenced by marked increases in FEV1 (% predicted) and ACT scores over time. The demographic characteristics, baseline respiratory symptoms, and treatment outcomes were similar between the groups, indicating that both strategies were equally effective for managing asthma. The findings indicate that both VI-FF once daily and FM-BD twice daily therapies enhance lung function and asthma control. Significant improvements in FEV1 (% predicted) and ACT scores were observed in both groups, as confirmed by intention-to-treat (ITT) and perprotocol (PPA) analyses. The equivalent efficacy of VI-FF and FM-BD, combined with the convenience of once-daily dosing, suggests that VI-FF may be preferable for patients who struggle with a twice-daily regimen. These findings highlight VI-FF as a convenient and reliable treatment, particularly can benefit patients with adherence challenges. In conclusion, our study's findings align well with other studies regarding demographic characteristics, baseline symptoms, exacerbation history, hospitalization history, and spirometry results. This consistency reinforces the validity and reliability of our results, suggesting that both VI-FF and FM-BD are effective options for stable asthma. The comparable efficacy supports flexibility in treatment choices, allowing for personalized asthma management. Future research should explore the long-term benefits and adherence patterns associated with these treatments to further optimize asthma management.

Article Subject Details

Article File